Noxopharm Limited
NOXOF · OTC
6/30/2024 | 6/30/2023 | 6/30/2022 | 6/30/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.07 | 0.04 | -0.08 | -0.01 |
| FCF Yield | -3.47% | -83.20% | -10.85% | -4.66% |
| EV / EBITDA | -3.79 | -0.69 | -7.54 | -11.39 |
| Quality | ||||
| ROIC | -136.08% | -129.55% | -48.26% | -39.83% |
| Gross Margin | -22.28% | 97.43% | 95.18% | 95.33% |
| Cash Conversion Ratio | 0.19 | 0.73 | 0.74 | 0.95 |
| Growth | ||||
| Revenue 3-Year CAGR | -23.82% | 2.33% | -13.13% | 14.35% |
| Free Cash Flow Growth | 93.75% | 20.29% | -55.17% | 20.56% |
| Safety | ||||
| Net Debt / EBITDA | 0.50 | 0.20 | 0.93 | 1.84 |
| Interest Coverage | -241.82 | -404.81 | -196.65 | -6.65 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.23 | 0.84 |
| Cash Conversion Cycle | -80.76 | -688.50 | 819.52 | -526.25 |